DYNAVAX TECHNOLOGIES CORP
Biopharma firm developing novel vaccines, like its adult hepatitis B vaccine, with adjuvant tech.
DVAX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US2681582019
- LEI:
- Country:
- United States of America
- Address:
- 2100 POWELL STREET, 94608 EMERYVILLE
- Website:
- https://www.dynavax.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Dynavax Technologies Corp. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel vaccines to prevent infectious diseases. Founded in 1996, the company's core strategy involves leveraging its proprietary Toll-like Receptor (TLR) stimulating adjuvant technology to enhance the body's innate and adaptive immune responses. Its primary commercial product is HEPLISAV-B®, an adjuvanted vaccine for the prevention of hepatitis B in adults. The company's CpG 1018® adjuvant is a key component of its technology platform and is also supplied to partners for use in other vaccines.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all DYNAVAX TECHNOLOGIES CORP filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DYNAVAX TECHNOLOGIES CORP
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DYNAVAX TECHNOLOGIES CORP via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
